Human Rise Pharma Private Limited
Pharmaceutical company trading medical products, founded in 2014 and located in Delhi.
2014 | Delhi (India) | Active
Human Rise Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 10 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth -43.58%
- Profit Growth -39.42%
- Ebitda -40.65%
- Net Worth 14.66%
- Total Assets 12.99%
About Human Rise Pharma
Human Rise Pharma Private Limited (HRPPL) is a Private Limited Indian Non-Government Company incorporated in India on 12 August 2014 and has a history of Ten years and six months. Its registered office is in Delhi, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Rakesh Tuteja, Baldev Tuteja, Sachin Arora, and One other member serve as directors at the Company.
Company Details
- Location
Delhi, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U74140DL2014PTC270268
- Company No.
270268
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
12 Aug 2014
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Pharma
Who are the key members and board of directors at Human Rise Pharma?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rakesh Tuteja  | Director | 12-Aug-2014 | Current |
| Baldev Tuteja | Director | 12-Aug-2014 | Current |
| Sachin Arora | Director | 12-Aug-2014 | Current |
| Sushil Kumar | Director | 12-Aug-2014 | Current |
Financial Performance of Human Rise Pharma.
Human Rise Pharma Private Limited, for the financial year ended 2021, experienced significant reduction in revenue, with a 43.58% decrease. The company also saw a substantial fall in profitability, with a 39.42% decrease in profit. The company's net worth Soared by an impressive increase of 14.66%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Human Rise Pharma?
In 2021, Human Rise Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
R.S.B. Pharma Private LimitedRakesh Tuteja, Baldev Tuteja and 1 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Human Rise Pharma?
Unlock and access historical data on people associated with Human Rise Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Human Rise Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Human Rise Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.